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ABSTRACT
Patient-derived xenograft (PDX) mouse models of cancer are emerging as an 
important component of personalized precision cancer therapy. However, most 
models currently offered to patients have their tumors subcutaneously-transplanted 
in immunodeficient mice, which rarely metastasize. In contrast, orthotopic-transplant 
patient-derived models, termed patient-derived orthotopic xenografts (PDOX), 
usually metastasize as in the patient. We demonstrate in the present report why 
orthotopic models are so important for the patient, since primary and metastatic 
tumors developed in an orthotopic model can have differential chemosensitivity, not 
detectable in standard subcutaneous tumor models. A subcutaneous nude mouse 
model of HER-2 expressing cervical carcinoma was not sensitive to entinostat (a 
benzamide histone deactylase inhibitor), which also did not inhibit primary tumor 
growth in a PDOX model of the same tumor. However, in the PDOX model, entinostat 
alone significantly reduced the metastatic tumor burden, compared to the control. 
Thus, only the PDOX model could be used to discover the anti-metastatic activity of 
entinostat for this patient. The results of the present report indicate the importance 
of using mouse models that can recapitulate metastatic cancer for precisely 
individualizing cancer therapy.
INTRODUCTION
Patient-derived xenograft (PDX) mouse models 
of cancer are emerging as an important potential aid to 
personalized cancer therapy. However, most models 
offered are subcutaneously (s.c.) transplanted patient 
tumors in immunodeficient mice, which rarely metastasize 
[1]. Discrepancies have been described for decades 
between the invasive and metastatic behavior of tumors in 
the patient compared to their benign behavior in the s.c.-
transplanted xenografts in immunocompetent mice [2]. 
More precise mouse models must be offered to the patient.
Wang and Sordat et al. [3] in 1982 were among 
the first to implant human tumors orthotopically (literally 
‘correct place’) in nude mice, using cancer-cell suspensions, 
rather than “heterotopically” (literally “different place,” 
such as s.c.) [3]. Metastases as well as local tumor growth 
occurred in the orthotopic model, a very important advance. 
Our laboratory pioneered the patient-derived orthotopic 
xenograft (PDOX) nude mouse model with the technique 
of surgical orthotopic implantation (SOI) of intact colon 
cancer tissue [4, 5]. A greater extent of metastasis was 
observed in orthotopic models with implanted intact 
tumor tissue compared with orthotopically-implanted cell 
suspensions of the same tumor [6]. This perhaps is due to 
the intact histology and cancer-cell stroma interaction of the 
orthotopically-implanted tumor tissue.
PDOX models from patients with colon [4], pancreatic 
[7], breast [8], ovarian [9], lung [10], stomach cancer [11], 
and mesothelioma [12] were established in the early 1990s 
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in our laboratory, resulting in primary and metastatic tumor 
growth very similar to that of the patient [11]. Recently, 
PDOX models of sarcoma have been developed [13–15] 
as well as additional models of pancreatic cancer PDOX 
[16–19] and colon cancer PDOX [5, 20]. 
We have also recently described the development 
of a PDOX model of HER2-positive cervical cancer. 
Metastasis in nude mice included peritoneal dissemination, 
liver metastasis, lung metastasis, as well as lymph node 
metastasis, reflecting the metastatic pattern in the donor 
patient. Primary tumors and metastases in the nude mice 
had histological structures similar to those in the original 
tumor and were stained by a HER2-specific antibody in 
the same pattern as was the patient’s original cancer [21].
In the present report, we describe that the benzamide 
histone deacetylase inhibitor, entinostat, was not active in 
a subcutaneous PDX nude mouse model of the HER-2 
expressing cervical carcinoma described above, nor did 
entinostat prevent primary tumor growth in the PDOX 
model of the same tumor. In contrast, in the PDOX model, 
entinostat significantly reduced the metastatic tumor 
burden compared to the control. Thus, only the PDOX 
model could be used to discover the anti-metastatic 
activity of entinostat for this patient. The results of the 
present report indicate the importance of using patient-
derived mouse models that can recapitulate metastatic 
cancer for precise personalized therapy.
RESULTS AND DISCUSSION
Treatment protocols are outlined in Figure 1. 
Entinostat did not arrest tumor growth in the 
subcutaneous model of patient cervical cancer
Entinostat monotherapy was least effective compared 
to carboplatin, trastuzumab and lapatinib in the subcutaneous 
nude mouse model of patient cervical cancer (Figure 2).
Entinostat monotherapy was not active on the 
primary tumor of the PDOX model of cervical 
cancer
All regimens tested except entinostat had significant 
efficacy on the primary tumors compared to the vehicle 
control group: carboplatin, P = 0.004; trastuzumab/lapatinib, 
P = 0.03; trastuzumab/lapatinib/entinostat, P < 0.001; 
respectively. Entinostat monotherapy compared to vehicle 
control, P = 0.262 (Figure 3).
Entinostat monotherapy was active against 
metastasis in the PDOX model of cervical cancer
However, entinostat had efficacy against metastasis in 
the PDOX model of cervical carcinoma. All other regimens 
Figure 1: Schema of experiments. The patient HER-2-expressing squamous carcinoma of the cervix was established subcutaneously 
in nude mice. Small fragments of subcutaneously-growing tumor were harvested, minced and orthotopically implanted in the cervix of 25 
nude mice. Six weeks after implantation, the mice in each model were randomized and treated in the following groups of n = 5: (1) saline 
(control, ip, weekly, 5 weeks); (2) carboplatin (30 mg/kg, ip, weekly, 5 weeks); (3) trastuzumab (20 mg/kg, ip, weekly, 5 weeks) + lapatinib 
(100 mg/kg, orally, daily, 5 weeks); (4) trastuzumab (20 mg/kg, ip, weekly, 5 weeks) + lapatinib (100 mg/kg, orally, daily, 5 weeks) + 
entinostat (5 mg/kg, orally, daily, 5 weeks); and (5) entinostat (5 mg/kg, orally, daily, 5 weeks). 
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tested also had significant efficacy on metastasis compared 
to the vehicle group: carboplatin, P = 0.005; trastuzumab/
lapatinib, P = 0.006; trastuzumab/lapatinib/entinostat, 
P = 0.027; entinostat, P = 0.018; respectively (Figure 3). 
No metastasis was detected in the trastuzumab/lapatinib/
entinostat group (Figure 3). All regimens caused body-
weight loss, with carboplatin the most toxic (Figure 3).
Histology
We previously examined the histology of the PDOX 
model using H&E staining and immunostaining with 
anti-HER2 antibody [21]. Sheet-like growth without 
gland formation fibroblastic cells, which penetrated into 
the nests of carcinoma, were found in the H&E stained 
Figure 2: Drug-efficacy testing in the subcutaneous tumor model. Representative images of nude mice with subcutaneous tumor 
before treatment (A), or treated with saline (B), carboplatin (C), trastuzumab + lapatinib (D), trastuzumab + lapatinib + entinostat (E) or 
entinostat (F). The areas surrounded by black broken lines indicate the subcutaneous tumors. Scale bar: 10 mm. (G) Growth curves of the 
subcutaneous PDXs treated with various drugs as described above. (n = 5 for each treatment arm). (H) Body weight curves of the mice with 
the subcutaneous PDXs treated with various drugs.
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Figure 3: Drug-efficacy testing in the PDOX model. Representative images of laparotomy of the nude mice with the PDOX treated 
with saline (A), carboplatin (B), trastuzumab + lapatinib (C), trastuzumab + lapatinib + entinostat (D), or entinostat (E). Black arrow heads 
or yellow arrow heads indicate primary tumors or peritoneally-disseminated tumors, respectively. (F–J) Excised specimens of primary 
tumors corresponding to Figures A–E, respectively. (K –N) Excised specimens of peritoneally-disseminated tumors corresponding to 
Figures A–E, respectively. Scale bar: 10 mm. (O) Bar graphs of the primary tumor weight in each group. (P) Bar graphs of the metastatic 
tumor weight in each group. (n = 5 for each treatment arm). (Q) Body weight curves of the mice with the PDOXs treated with various 
drugs. *p < 0.05, **p < 0.01.
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sections of the original tumor. A range of oval- to spindle-
shaped cancer cells with high nuclear/cytoplasmic 
ratios were observed in high-magnification images. 
Immunohistochemistry with an anti-HER-2 antibody 
showed that the membrane and the cytoplasm of cancer 
cells was strongly stained but no staining was found in the 
stromal tissue. The mouse-grown primary and metastatic 
tumors had histological structures similar to the original 
tumor and were stained by anti-HER-2 antibody (Figure 
4B–4D) [21]. 
MATERIALS AND METHODS
Animals
Female athymic nu/nu nude mice (AntiCancer Inc., 
San Diego, CA), 4–6 weeks old, were used in this study. 
Mice were kept in a barrier facility under HEPA filtration. 
Mice were fed with autoclaved laboratory rodent diet. All 
mouse surgical procedures and imaging were performed 
with the animals anesthetized by intramuscular injection 
of a 0.02 ml solution of 50% ketamine, 38% xylazine, 
and 12% acepromazine maleate. All animal studies were 
conducted with an AntiCancer Institutional Animal Care 
and Use Committee (IACUC)-protocol specifically 
approved for this study and in accordance with the 
principals and procedures outlined in the National Institute 
of Health Guide for the Care and Use of Animals under 
Assurance Number A3873-1.
Patient consent and IRB approval
The patient with HER-2-expressing cervical cancer 
provided informed consent and the study was conducted 
under the approval of the Institutional Review Board 
(IRB) of the UC San Diego Medical Center.
Establishment of patient-derived cervical cancer
Tumor tissues were obtained from the HER-2-
positive cervical cancer patient at surgery, divided into 
3-mm3 fragments, and transplanted subcutaneously in 
nude mice [21].
Orthotopic tumor implantation
After the subcutaneous tumors grew in the nude 
mice, they were harvested and divided into small 
fragments for orthotopic transplantation which was 
performed as follows: a small 6− to 10-mm midline 
incision was made on the lower abdomen of the nude 
mouse through the skin and peritoneum. The uterus was 
exposed through this incision, and a single 3-mm3 tumor 
fragment was sutured to the cervix of the uterus using 8–0 
nylon surgical sutures (Ethilon; Ethicon Inc., NJ, USA). 
On completion of tumor implantation, the uterus was 
returned to the abdomen, and the incision was closed in 
one layer using 6–0 nylon surgical sutures (Ethilon) [21].
Treatment
Six weeks after implantation, the mice in the PDX 
and PDOX models were randomized and treated in the 
following groups of n = 5: (1) saline control, (ip, weekly, 5 
weeks); (2) carboplatin (Selleck Chemicals, Houston, TX, 
USA, 30 mg/kg, ip, weekly, 5 weeks); (3) trastuzumab 
(Genentech, Inc., South San Francisco, CA, USA, 20 mg/
kg, ip, weekly, 5 weeks) + lapatinib (Selleck Chemicals, 
100 mg/kg, orally, daily, 5 weeks); (4) trastuzumab (20 
mg/kg, ip, weekly, 5 weeks) + lapatinib (100 mg/kg, 
orally, daily, 5 weeks) + entinostat (Selleck Chemicals, 5 
mg/kg, orally, daily, 5 weeks); and (5) entinostat (5 mg/
kg, orally, daily, 5 weeks) (Figure 1). For the subcutaneous 
Figure 4: Histology of the patient and mouse-grown tumors and metastasis. H&E-stained and immunostained sections of 
mouse-grown tumors. Upper panels are H&E-stained sections and lower panels are immunostained sections using an anti-HER-2 antibody. 
Right upper insets are high-magnification images (scale bars: 25 μm). All mouse-grown tumors, including the subcutaneous tumors (A), 
primary orthotopic tumor (B), peritoneal-disseminated metastasis (C) and liver metastasis (D) had histological structures similar to the 
original patient tumor and were stained by an anti-HER-2 antibody. Scale bars: 200 μm (A–D, lower magnification) [21]. 
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model, tumor size was evaluated every 3 or 4 days by 
caliper measurements and the approximate tumor volume 
was calculated using the formula 4/3π.(d/2)2. D/2, where 
d is the minor tumor axis and D is the major tumor axis.
For the orthotopic model, the mice underwent 
laparotomy 1 week before treatment to confirm the 
presence of the primary tumor, and its size was evaluated 
as described above.
Relative tumor volume and body weight were 
calculated by comparison to tumor size before treatment. 
Animals underwent laparotomy after treatment, and the 
tumors were photographed with a Canon EOS 60D digital 
camera with an EF–S18–55 IS lens (Canon, Tokyo, Japan) 
and weighed and harvested for analysis. Body weight of 
the mice was measured in a balance once a week.
Tissue histology
Tumor samples were removed with surrounding 
normal tissues at the time of resection. Fresh tissue 
samples were fixed in 10% formalin and embedded in 
paraffin before sectioning and staining. Tissue sections 
(3 μm) were deparaffinized in xylene and rehydrated 
in an ethanol series. Hematoxylin and eosin (H&E) 
staining was performed according to standard protocols. 
For immunohistochemistry, the sections were then 
treated for 30 min with 0.3% hydrogen peroxide to 
block endogenous peroxidase activity. The sections 
were subsequently washed with PBS and incubated in 
citrate antigen unmasking solution (Mitsubishi Kagaku 
Iatron, Inc., Tokyo, Japan) in a water bath for 40 min 
at 98°C. After incubation with 10% normal goat serum, 
the sections were incubated with anti-HER-2/ErbB-2 
antibody (1:100, Cell Signaling Technology, Danvers, 
MA, USA) at 4°C overnight. The binding of primary 
antibodies was detected using anti-mouse secondary 
antibodies and avidin/biotin/horseradish peroxidase 
complex (DAKO Cytomation, Kyoto, Japan) for 30 min 
at room temperature. The labeled antigens were visualized 
with the DAB kit (DAKO Cytomation). Finally, the 
sections were counterstained with hematoxylin and 
examined using an Olympus BH-2 microscope equipped 
with an INFINITY1 2.0 megapixel CMOS digital camera 
(Lumenera Corporation, Ottawa, Canada). All images 
were acquired using INFINITY ANALYZE software 
(Lumenera Corporation) without post-acquisition 
processing (Figure 4).
Statistical analysis
PASW Statistics 18.0 (SPSS, Inc.) was used for 
all statistical analyses. The Student’s t-test was used 
to compare continuous variables between two groups. 
Analysis of variance models were used to compare 
multiple groups. A P-value of 0.05 was considered 
statistically significant for all comparisons.
CONCLUSIONS
The PDOX model recapitulated the metastatic 
potential of the original cervical-cancer patient tumor 
(Figure 3) [21]. Most importantly, entinostat monotherapy 
significantly inhibited the metastasis of HER-2-positive 
cervical cancer even though there was no efficacy of this 
agent on the primary tumor or on the subcutaneous model. 
The efficacy of entinostat would not have been detected in 
a subcutaneous PDX model of this tumor.
Patient-derived mouse models of cancer are an 
emerging field for individualized precise treatment of 
cancer. Although such models were first described in 1969 
[2], patient-derived models are now recognized for their 
potential in individualized, precision cancer treatment. 
The present report indicates the importance of orthotopic 
mouse models for their potential to most precisely 
represent the cancer patient for individualized therapy, 
most importantly to evaluate targeted anti-metastatic 
therapy. Future studies will measure tumor growth as 
a 3-dimensional geometric mean to better determine 
logarithmic growth. 
Previously-developed concepts and strategies of 
highly-selective tumor targeting can take advantage of 
molecular targeting of tumors, including tissue-selective 
therapy which focuses on unique differences between 
normal and tumor tissues [22–27]. 
ACKNOWLEDGMENTS
This study was supported in part by National 
Cancer Institute grant CA126023 and JSPS KAKENHI 
Grant Numbers 26830081 to Y.H., 26462070 to I.E and 
24592009 to K.T.
CONFLICTS OF INTEREST
The authors have no conflicts to disclose. 
DEDICATION
This paper is dedicated to the memory of A. R. 
Moossa, M.D., and Sun Lee, M.D.
REFERENCES
1. Hoffman RM. Patient-derived orthotopic xenografts: better 
mimic of metastasis than subcutaneous xenografts. Nature 
Reviews Cancer. 2015; 15:451–452.
2. Rygaard J, Povlsen CO. Heterotransplantation of a human 
malignant tumour to “nude” mice. Acta Path Microbiol 
Scand. 1969; 77:758–760.
3. Wang WR, Sordat B, Piguet D, Sordat M. Human colon 
tumors in nude mice: implantation site expression of the 
invasiveness phenotype. In: Immune-Deficient Animals. 4th 
Oncotarget71702www.impactjournals.com/oncotarget
Int. Workshop on Immune-Deficient Animals in Exp. Res., 
Chexbres. 1982; pp 239–244 (Karger, Basel, 1984). 
 4. Fu XY, Besterman JM, Monosov A, Hoffman RM. 
Models of human metastatic colon cancer in nude mice 
orthotopically constructed by using histologically intact 
patient specimens. Proc Natl Acad Sci USA. 1991; 
88:9345–9349.
 5. Metildi CA, Kaushal S, Luiken GA, Talamini MA, 
Hoffman RM, Bouvet M. Fluorescently-labeled chimeric 
anti-CEA antibody improves detection and resection of human 
colon cancer in a patient-derived orthotopic xenograft (PDOX) 
nude mouse model. J Surg Oncol 2014; 109:451–458.
 6. Furukawa T, Fu X, Kubota T, Watanabe M, Kitajima M, 
Hoffman RM. Nude mouse metastatic models of human 
stomach cancer constructed using orthotopic implantation of 
histologically intact tissue. Cancer Res. 1993; 53:1204–1208.
 7. Fu X, Guadagni F, Hoffman RM. A metastatic nude-
mouse model of human pancreatic cancer constructed 
orthotopically from histologically intact patient specimens. 
Proc Natl Acad Sci USA. 1992; 89:5645–5649.
 8. Fu X, Le P, Hoffman RM. A metastatic-orthotopic transplant 
nude-mouse model of human patient breast cancer. 
Anticancer Res. 1993; 13:901–904.
 9. Fu X, Hoffman RM. Human ovarian carcinoma 
metastatic models constructed in nude mice by orthotopic 
transplantation of histologically-intact patient specimens. 
Anticancer Res. 1993; 13:283–286.
10.  Wang X, Fu X, Hoffman RM. A new patient-like metastatic 
model of human lung cancer constructed orthotopically 
with intact tissue via thoracotomy in immunodeficient mice. 
Int J Cancer. 1992; 51:992–995.
11. Furukawa T, Kubota T, Watanabe M, Kitajima M, Fu X, 
Hoffman RM. Orthotopic transplantation of histologically 
intact clinical specimens of stomach cancer to nude mice: 
correlation of metastatic sites in mouse and individual 
patient donors. Int J Cancer. 1993; 53:608–612.
12. Astoul P, Wang X, Colt HG, Boutin C, Hoffman RM. A 
patient-like human malignant pleural mesothelioma nude-
mouse model. Oncology Reports. 1996; 3:483–487.
13. Murakami T, DeLong J, Eilber FC, Zhao M, Zhang Y, Zhang 
N, Singh A, Russell T, Deng S, Reynoso J, Quan C, Hiroshima 
Y, Matsuyama R, et al. Tumor-targeting Salmonella 
typhimurium A1-R in combination with doxorubicin eradicate 
soft tissue sarcoma in a patient-derived orthotopic xenograft 
PDOX model. Oncotarget. 2016; 7:12783–12790. doi: 
10.18632/oncotarget.7226.
14. Kiyuna T, Murakami T, Tome Y, Kawaguchi K, Igarashi 
K, Zhang Y Zhao M, Li Y, Bouvet M, Kanaya F, Singh A, 
Dry S, Eilber FC, Hoffman RM. High efficacy of tumor-
targeting Salmonella typhimurium A1-R on a doxorubicin- 
and dactolisib-resistant follicular dendritic-cell sarcoma in 
a patient-derived orthotopic xenograft PDOX nude mouse 
model. Oncotarget. 2016; 7:33046–33054. doi: 10.18632/
oncotarget.8848.
15. Murakami T, Singh AS, Kiyuna T, Dry SM, Li Y, James A,W, 
Igarashi K, Kawaguchi K, DeLong JC, Zhang Y, Hiroshima Y, 
Russell T, et al. Effective molecular targeting of CDK4/6 
and IGF-1R in a rare FUS-ERG fusion CDKN2A-deletion 
doxorubicin-resistant Ewing’s sarcoma in a patient-derived 
orthotopic xenograft (PDOX) nude-mouse model. Oncotarget. 
2016; 7:47556–47564. doi: 10.18632/oncotarget.9879.
16. Kim MP, Evans DB, Wang H, Abbruzzese JL, Fleming 
JB, Gallick GE. Generation of orthotopic and heterotopic 
human pancreatic cancer xenografts in immunodeficient 
mice. Nature Protocols. 2009; 4:1670–1680.
17. Kim MP, Truty MJ, Choi W, Kang Y, Chopin-Lally X, 
Gallick GE, Wang H, McConkey DJ, Hwang R, Logsdon C, 
Abbruzzesse J, Fleming JB. Molecular profiling of direct 
xenograft tumors established from human pancreatic 
adenocarcinoma after neoadjuvant therapy. Ann Surg 
Oncol. 2012; 19:S395–S403.
18. Hiroshima Y, Maawy A, Sato S, Murakami T, Uehara F, 
Miwa S, Yano, S, Momiyama M, Chishima T, Tanaka K, 
Bouvet M, Endo I, et al. Hand-held high-resolution 
fluorescence imaging system for fluorescence-guided 
surgery of patient and cell-line pancreatic tumors growing 
orthotopically in nude mice. J Surg Res. 2014; 187:510–517.
19. Hiroshima Y, Zhao M, Maawy A, Zhang Y, Katz MH, 
Fleming JB, Uehara F, Miwa S, Yano S, Momiyama M, 
Suetsugu A, Chishima T, Tanaka K, et al. Efficacy of 
Salmonella typhimurium A1-R versus chemotherapy on 
a pancreatic cancer patient-derived orthotopic xenograft 
(PDOX). J Cell Biochem. 2014; 115:1254–1261.
20. Hiroshima Y, Maawy A, Metildi CA, Zhang Y, Uehara F, 
Miwa S, Yano S, Sato S, Murakami T, Momiyama M, 
Chishima T, Tanaka K, Bouvet M, et al. Successful 
fluorescence-guided surgery on human colon cancer 
patient-derived orthotopic xenograft mouse models using 
a fluorophore-conjugated anti-CEA antibody and a portable 
imaging system. J Laparoendosc Adv Surg Tech. A 2014; 
24:241–247.
21. Hiroshima Y, Zhang Y, Zhang M, Maawy A, Mii S, 
Yamamoto M, Uehara F, Miwa S, Yano S, Murakami T, 
Momiyama M, Chishima T, Tanaka K, et al. Establishment 
of a patient-derived orthotopic xenograph (PDOX) model 
of HER-2-positive cervical cancer expressing the clinical 
metastatic pattern. Plos One. 2015; 10:e0117417.
22. Blagosklonny MV. Matching targets for selective cancer 
therapy. Drug Discov Today 2003; 8:1104–1107.
23. Blagosklonny MV. Teratogens as anti-cancer drugs. Cell 
Cycle. 2005; 4:1518–1521.
24. Blagosklonny MV. Treatment with inhibitors of caspases, 
that are substrates of drug transporters, selectively permits 
chemotherapy-induced apoptosis in multidrug-resistant cells 
but protects normal cells. Leukemia. 2001; 15:936–941.
25. Blagosklonny MV. Target for cancer therapy: proliferating 
cells or stem cells. Leukemia. 2006; 20:385–391.
26. Apontes P, Leontieva OV, Demidenko ZN, Li F, 
Blagosklonny MV. Exploring long-term protection 
of normal human fibroblasts and epithelial cells from 
chemotherapy in cell culture. Oncotarget 2011; 2:222–233. 
doi: 10.18632/oncotarget.248.
27. Blagosklonny MV. Tissue-selective therapy of cancer. Br J 
Cancer. 2003; 89:1147–1151.
